Flagship Pioneering’s Moderna MRNA Stock Holding History

Flagship Pioneering’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$324M	Hold	4,632,149	–	–	21.07%	2
2026 Q1	$235M	Hold	4,632,149	–	–	20.26%	2
2025 Q4	$137M	Hold	4,632,149	–	–	42.16%	1
2025 Q3	$120M	Hold	4,632,149	–	–	40.89%	1
2025 Q2	$128M	Hold	4,632,149	–	–	47.6%	1
2025 Q1	$131M	Hold	4,632,149	–	–	55.7%	1
2024 Q4	$193M	Hold	4,632,149	–	–	57.63%	1
2024 Q3	$310M	Hold	4,632,149	–	–	52.3%	1
2024 Q2	$550M	Sell	4,632,149 -5,033,889	-52%	-$637M	65.22%	1
2024 Q1	$1.03B	Hold	9,666,038	–	–	67.56%	1
2023 Q4	$961M	Hold	9,666,038	–	–	72.53%	1
2023 Q3	$998M	Sell	9,666,038 -3,220,705	-25%	-$359M	72.47%	1
2023 Q2	$1.57B	Hold	12,886,743	–	–	69.88%	1
2023 Q1	$1.98B	Hold	12,886,743	–	–	76.91%	1
2022 Q4	$2.31B	Hold	12,886,743	–	–	73.9%	1
2022 Q3	$1.52B	Hold	12,886,743	–	–	64.14%	1
2022 Q2	$1.84B	Sell	12,886,743 -4,694,273	-27%	-$671M	69.35%	1
2022 Q1	$3.03B	Hold	17,581,016	–	–	71.11%	1
2021 Q4	$4.47B	Hold	17,581,016	–	–	69.04%	1
2021 Q3	$6.77B	Sell	17,581,016 -3,000,000	-15%	-$1.11B	70.86%	1
2021 Q2	$4.84B	Hold	20,581,016	–	–	61.77%	1
2021 Q1	$2.7B	Sell	20,581,016 -10,290,508	-33%	-$1.49B	43.16%	1
2020 Q4	$3.23B	Hold	30,871,524	–	–	58.71%	1
2020 Q3	$2.18B	Sell	30,871,524 -9,000,000	-23%	-$628M	60.34%	1
2020 Q2	$2.56B	Sell	39,871,524 -11,000,000	-22%	-$602M	74.39%	1
2020 Q1	$1.52B	Hold	50,871,524	–	–	71.42%	1
2019 Q4	$995M	Sell	50,871,524 -7,935,855	-13%	-$141M	55.62%	1
2019 Q3	$936M	Hold	58,807,379	–	–	51.21%	1
2019 Q2	$861M	Hold	58,807,379	–	–	37.27%	1
2019 Q1	$1.2B	Hold	58,807,379	–	–	45.29%	1
2018 Q4	$898M	Buy	+58,807,379	New	+$966M	43.86%	1

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Flagship Pioneering's MRNA Position: Q2 2026 in Review

Flagship Pioneering held its Moderna (MRNA) position steady in Q2 2026 at 4,632,149 shares worth $324M. The position accounts for 21.07% of the portfolio, ranked #2.

Flagship Pioneering first reported a position in MRNA in Q4 2018 and has held it in 31 quarters since. The position peaked at $6.77B in Q3 2021. 777 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Flagship Pioneering held 4,632,149 shares of Moderna worth $324M as of Q2 2026.
Flagship Pioneering left its Moderna share count unchanged in Q2 2026.
Moderna made up 21.07% of Flagship Pioneering's portfolio in Q2 2026, its #2 holding.
Flagship Pioneering first reported a position in Moderna in Q4 2018 and has held it in 31 quarters since.
Flagship Pioneering's Moderna position peaked at $6.77B in Q3 2021.
777 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Flagship Pioneering's 13F filing for Q2 2026, filed 14 Aug 2026.